z-logo
open-access-imgOpen Access
PHARMACOLOGICAL EVALUATION OF PIRACETAM AND VANADYL SULFATE ON EXPERIMENTALLY INDUCED CEREBRAL ISCHEMIA IN RATS
Author(s) -
Banappa S. Unger,
M. Hima Saila
Publication year - 2016
Publication title -
international journal of pharmacy and pharmaceutical sciences/international journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2656-0097
pISSN - 0975-1491
DOI - 10.22159/ijpps.2016v8i9.12875
Subject(s) - piracetam , ischemia , chemistry , lipid peroxidation , superoxide dismutase , glutathione , pharmacology , antioxidant , catalase , oxidative stress , endocrinology , medicine , biochemistry , enzyme
Objective: The aim of present study was designed to evaluate the combinatorial effect of piracetam and vanadyl sulfate on experimentally induced global cerebral ischemia in rats. Methods: Piracetam (600 mg/kg, p. o.) and vanadyl sulfate (22.4 mg/kg, p. o.) were administered individually and also in combination before the induction of ischemia. Cerebral ischemia was induced by bilateral carotid artery (BCA) occlusion for 30 min followed by reperfusion 60 min. Results: The antioxidant and non-antioxidant enzymatic levels were estimated along with histopathological studies. The concomitant pretreated group showed a more significant decrease in lipid peroxidation (LPO) and increased in the superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and total thiol levels as compared to ischemic reperfusion group. Histopathological damage was significantly reduced in drug treated groups as compared to ischemia-reperfusion group. Conclusion: The findings of the present study suggest that pretreatment with piracetam and vanadyl sulfate in combination prevents the ischemia-reperfusion injury and prevented oxidative tissue damage as shown by decreased lipid peroxides, restored the antioxidant levels, histological changes such as infarct area, inflammatory changes, and edema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here